Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • 会社
  • 私たちのストーリー
  • Stories
  • From traditional roots to modern impact: organoids meet TCM research.
challenge accept story hero

Story

Small Molecule Drug Discovery

From traditional roots to modern impact: organoids meet TCM research.

Some knowledge is inherited.
Some must be validated.

For centuries, Traditional Chinese Medicine has relied on observation, experience, and trust built across generations. But today’s research environment asks for something more: measurable outcomes, reproducibility, and scalable biological validation.

At Anhui University of Chinese Medicine, researchers weren’t trying to modernize tradition for the sake of modernization. They were working to build something stronger, a bridge between centuries of medical wisdom and the precision standards required in contemporary science.

Their ambition was clear: develop a high-standard, organoid-based Bio-Functional Evaluation Platform capable of compound screening, efficacy validation, and advanced in vitro modeling tailored specifically to the complexity of TCM research.

The obstacle wasn’t knowledge.
It was the tools supporting it.

Manual workflows slowed throughput. Variability limited reproducibility. Conventional drug discovery tools weren’t designed for multi-component TCM formulations. The science was ready to evolve, but the systems weren’t.

To move forward, the university needed more than a new instrument.

They needed technology that could adapt to their research model, and a partner willing to build alongside them.

Designing around the research, not the equipment

The collaboration began with listening.

Where did workflow friction occur?
What level of automation would meaningfully accelerate organoid screening?
How could precision be improved without compromising biological complexity?

Through hands-on consultation, scenario-based workshops, and technical evaluation, the solution centered on the Explorer™ G3 system, not as a standalone device, but as the foundation of an automated organoid workflow built for consistency and scale.

Its differentiation wasn’t just in capability, but in alignment:

  • Automated liquid handling to increase throughput and reduce manual variability
  • Dispensing suited for complex compound matrices
  • Flexible configuration to accommodate customized TCM evaluation protocols
  • Scalability to support both exploratory research and standardized validation

Implementation support extended beyond installation. Documentation and procurement were streamlined. Training focused on integration, ensuring the system became part of a daily research rhythm, not a disruption to it.

This wasn’t about placing technology.

It was about enabling progress.

Setting a New Standard

The milestone is notable: the first Explorer G3 system placed within a Traditional Chinese Medicine research setting.

But the true impact goes deeper.

The university now operates with greater automation, and more efficient screening workflows. Organoid modeling supports higher scientific standards. Biological validation is more consistent and scalable.

And beyond one laboratory, a precedent has been established.

This platform demonstrates that advanced organoid technologies can elevate TCM research without diminishing its foundation. It offers a replicable model for institutions seeking to integrate traditional medical insight with globally recognized scientific rigor.

Modernization does not erase history.

It strengthens it.

The future tradition deserves

Tradition carries authority.
Science carries proof.

When brought together with intention, they don’t compete. They compound.

At Anhui University of Chinese Medicine, centuries of wisdom now move forward with automation, consistency, and confidence, not to rewrite history, but to validate it. And thanks to technology tailored to their goals and support that stayed with them every step of the way, they can now focus on insights instead of obstacles.

Because the future of research isn’t about choosing between legacy and innovation.

It’s about building the bridge that allows both to thrive.

For research use only. Not for use in diagnostic procedures.
 

More about organoids
More stories

Share this post:

  • Email
  • Facebook
  • Linkedin
  • Twitter
Recent Stories
The unsung hero behind accurate cancer diagnoses: why reference standards matter.
Read
When a breakthrough begins with a question: how a customer conversation sparked a new way forward.
Read
A new era in newborn screening: how DNA sequencing can change the first days of life.
Read
line

ご質問がございましたら、
お気軽にお問い合わせください。

お問合せ
Revvity Logo

©2026 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.